ClinicalTrials.gg
RecruitingNCT05584800Updated Jan 5, 2026

Study of ZGGS18 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ZGGS18 for Injection and ZGGS18 for Injection in Advanced Solid Tumor, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
222
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced solid tumors, who had failed the available standard treatments or no standard treatment or intolerance to standard treatment;
  • (ECOG) Performance Status of 0 or 1;
  • ≥ 3 months;
  • Must have at least 1 per 1.1(RECIST1.1). For lesions that have received radiation therapy, only after the progression of the lesions, they can be considered measurable lesions.

Exclusion criteria

Exclusion Criteria:

  • The investigator considers that any subjects are not suitable to participate in the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Biological: ZGGS18 for Injection

  • Experimental
    Dose Expansion

    Tumor type: colorectal cancer,pancreatic cancer

    Biological: ZGGS18 for Injection

Interventions

  • BiologicalZGGS18 for Injection

    0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18,intravenous infusion, once every 2 weeks.

  • BiologicalZGGS18 for Injection

    Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18,intravenous infusion, once every 2 weeks.

06

What researchers measure

Primary outcomes

  1. Tolerability of ZGGS18

    Dose limiting toxicity, number of participants with abnormal laboratory values and/or adverse events that are related to treatment

    Time frame: 28 days

  2. Safety of ZGGS18

    Number of participants with adverse events/abnormal laboratory values that are related to treatment

    Time frame: Through study completion, an expected average of 3 years

Secondary outcomes

  1. Pharmacokinetic characteristics of ZGGS18

    Peak Plasma Concentration (Cmax)

    Time frame: Through Phase I study completion, an expected average of 1 year

  2. Pharmacokinetic characteristics of ZGGS18

    Time to maximum concentration (Tmax)

    Time frame: Through Phase I study completion, an expected average of 1 year

  3. Pharmacokinetic characteristics of ZGGS18

    Clearance (CL/F)

    Time frame: Through Phase I study completion, an expected average of 1 year

  4. Pharmacokinetic characteristics of ZGGS18

    Area under drug concentration-time curve

    Time frame: Through Phase I study completion, an expected average of 1 year

  5. Pharmacokinetic characteristics of ZGGS18

    Elimination rate constant (Ke)

    Time frame: Through Phase I study completion, an expected average of 1 year

  6. Pharmacokinetic characteristics of ZGGS18

    Elimination half-life (t1/2)

    Time frame: Through Phase I study completion, an expected average of 1 year

  7. Immunogenicity of ZGGS18

    Detection of anti-drug antibodies, if positive, further detection of neutralizing antibodies. Counting the number of patients and incidence of anti-drug antibodies and neutralizing antibodies

    Time frame: Through study completion, an expected average of 3 years

  8. Efficacy of ZGGS18

    Objective response rate

    Time frame: Through study completion, an expected average of 3 years

  9. Efficacy of ZGGS18

    Progression-free survival

    Time frame: Through study completion, an expected average of 3 years

  10. Efficacy of ZGGS18

    Disease control rate

    Time frame: Through study completion, an expected average of 3 years

  11. Efficacy of ZGGS18

    Duration of response

    Time frame: Through study completion, an expected average of 3 years

  12. Efficacy of ZGGS18

    Time to response

    Time frame: Through study completion, an expected average of 3 years

  13. Efficacy of ZGGS18

    Time to progression

    Time frame: Through study completion, an expected average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 18, 2022
StartActual
Nov 15, 2022
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584800
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Nov 15, 2022
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

Shangdi Ning
Contact
ningsd@zelgen.com
+86-0512-57018308
Jason Wu
study director · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion